TRIAL DETAIL

Phase I, Combining Oral Topotecan With Oral Pazopanib

Drug:
Trial Name:
Phase I, Combining Oral Topotecan With Oral Pazopanib
NCT#:
Conditions:
Any type of Cancer
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 09/01/2008
Age of Trial (yrs) 13.3
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor + topoisomerase inhibitor
Strategy:
Block KIT + Unblock cell death genes
Trial Type:
GIST not specified. GIST patients known to be enrolled.
Other Protocol IDs:
HYT109091
Sponsor:
GlaxoSmithKline
Patient Contact:
US GSK Clinical Trials Call Center
Contact email:
Contact Phone:
877-379-3718
Randomized:
IV or Oral:
Trial Notes:
This is a phase I trial to test the safety and maximum tolerated dose of the combination of pazopanib (Vortrient) and Toptecan.

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
Amsterdam
Netherlands
Heidelberglaan 100
Utrecht
3584 CX
Netherlands
38th and Walnut Streets
Philadelphia
PA
19104
USA